- Report of Foreign Issuer (6-K)
October 22 2008 - 6:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________________________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For the
month of October, 2008
Commission
File Number
________________
Novogen
Limited
(Translation
of registrant’s name into English)
140 Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):
o
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7):
o
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes
o
No
x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf
by the undersigned, thereunto duly
authorized.
Novogen
Limited
(Registrant)
/s/ Ron
Erratt
Ronald
Lea Erratt
Company
Secretary
Date
21 October, 2008
ASX
& MEDIA RELEASE
21
OCTOBER, 2008
GLYCOTEX
FINALISES COLLABORATION AGREEMENT WITH ADVANCED MEDICAL SOLUTIONS
Novogen
Limited’s subsidiary, Glycotex, Inc., has made the following
announcement:
Rockville,
MD – October 17, 2008 - Glycotex, Inc. today announced that it has finalized an
agreement with U.K.-based Advanced Medical Solutions (AMS) to study the use of
GLYC-101 with wound dressings manufactured by AMS.
Through
this collaboration, Glycotex and AMS have agreed to an initial phase of testing
of the use of GLYC-101 with AMS’ wound dressings. Under the
agreement, in the event that this first phase of testing gives rise to favorable
results, or generates data that suggest further research may be warranted,
Glycotex and AMS will have an opportunity to extend their collaboration for the
purposes of continued research.
About
GLYC-101
GLYC-101
is intended to stimulate and modulate the natural cascade of wound healing
activities of several cell populations. The product candidate currently
under development is a topical gel to be applied directly on the wound
surface. The strategic priorities for GLYC-101 include wound healing
following laser ablation, burn wounds, surgical wounds, venous ulcers and
diabetic ulcers.
In May
2006, Glycotex completed a Phase II clinical trial of GLYC-101 in
Australia, in which GLYC-101 produced a statistically significant rate of wound
area reduction versus combined placebo and standard care in patients with
chronic venous ulcers. The results provided proof-of concept and
dose-ranging information for GLYC-101. In U.S. clinical trials,
GLYC-101 is being assessed for safety and effectiveness on wound closure in
patients undergoing carbon dioxide laser skin resurfacing.
About
Advanced Medical Solutions
Advanced
Medical Solutions is a leading company in the development and manufacture of
products for the $15 billion global woundcare market.
Founded
in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design,
development and manufacture of innovative and technologically advanced woundcare
products.
In-house
natural and synthetic polymer technology is used to provide advanced wound
dressings based on the moist healing principle. AMS’ resources ensure
a unique position as a vertically integrated ‘one stop shop’ to provide all
categories of moist wound healing products. AMS has the capability to
move a product from design and development through to production and delivery
for distribution and sale into customer markets.
The
acquisition of 49.4 percent of Corpura BV in May 2008 strengthened AMS’ position
in hydrophilic polyurethane foam – the largest and fastest growing segment of
the advanced woundcare market.
AMS’
technology in cyanoacrylate based tissue adhesives is used either for the
closure of small cuts and trauma wounds through to large surgical incisions, or
for protecting or sealing skin to prevent breakdown or infection.
AMS’
products currently serve the majority of the key global markets sold either
direct or through strategic partners or distributors. For more
information, visit
www.admedsol.com
.
About
Glycotex, Inc.
Glycotex,
Inc. is a U.S. based development stage biopharmaceutical company focused on
discovering and developing therapies intended to accelerate human wound healing
and tissue repair across a wide range of human applications. It has
licensed from Novogen Limited certain patent rights and know-how to use and
exploit its technology in a wide range of wound healing applications. Glycotex,
Inc. is an 81 percent owned subsidiary of Novogen Limited. For more information,
visit
www.glycotexinc.com
.
Under
U.S. law, a new drug cannot be marketed until it has been investigated in
clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not
historical in nature are "forward-looking statements" within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. You should be aware that our actual results could differ materially from
those contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates, costs and delays in the development and/or
FDA approval, or the failure of our products to obtain such approval,
uncertainties in clinical trial results, our inability to maintain or enter
into, and the risks resulting from, our dependence upon, collaboration or
contractual arrangements necessary for the development, manufacture,
commercialization, marketing, sales and distribution of any products,
competitive factors, our inability to protect our patents or proprietary rights
and obtain necessary rights to third party patents and intellectual property to
operate our business, our inability to operate our business without infringing
the patents and proprietary rights of others, general economic conditions, the
failure of any products to gain market acceptance, our inability to obtain any
additional required financing, technological changes, government regulation,
changes in industry practice and one-time events. We do not intend to
update any of these factors or to publicly announce the results of any revisions
to these forward-looking statements.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024